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PRACTICAL PEARL: Allergic Rhinitis 
INTRODUCTION  Allergic rhinitis (AR) occurs in 78% of asthma patients.  
 AR is an IgE antibody-mediated, inflammatory disease.  
 Symptoms: nasal congestion, rhinorrhea (anterior and posterior), 
sneezing and itching. 
 Occurrence might be seasonal (pollen), perennial (indoor allergens) 
or episodic (intermittent allergen exposure). 
INITIAL EVALUATION AND 
MANAGEMENT BY 
PRIMARY CARE  
 Identify triggers by history, laboratory or skin testing. 
 Initiate allergen avoidance. 
 Start oral antihistamines alone as initial treatment. 
 If symptoms are poorly controlled, stop oral antihistamine and start 
intranasal steroids (INCS). 
 Long term INCS therapy requires monitoring of eye complications 
and linear growth. 
 Adding an oral antihistamine to an INCS, even if symptoms are 
incompletely controlled, does not add clinical benefit. 
 If poorly controlled with persistent use of INCS then add intranasal 
antihistamine (INAH). 
 Clinicians should not offer LTRA (i.e. montelukast) as primary 
therapy; INCSs are more effective than LTRAs across the range of 
allergy sx.     https://www.ncbi.nlm.nih.gov 
WHEN TO REFER   If AR persists or if AR is well controlled but asthma control is 
difficult to achieve.  
HOW TO REFER  (413) 794-KIDS  
 Pediatric Pulmonology 
WHAT TO EXPECT FROM BAYSTATE 
CHILDREN’S HOSPITAL VISIT 
  We can assist in allergen identification and avoidance education. 
 Assess lung function in asthmatics and assist in achieving control. 
 
 
